埃里亚宁通过JAK2-STAT3通路改善了吗啡耐受性和质瘤进展

Yi Gu¹, Jin Xu², Xiaoli Ding³

¹School of Life Science and Technology, China Pharmaceutical University, 639 Longmian Road, Nanjing, Jiangsu Province 211198, China; Room 702, Yimai Digital Mansion, Litanghe Road, Xiangcheng District, Suzhou, Jiangsu Province 215131, China.

Translational oncology

|September 30, 2025

概括

埃里安宁有效地对抗吗啡耐受性,并通过向JAK2/STAT3通路来减缓质瘤的生长. 这项研究为瘤学中的疼痛管理提供了新的治疗策略,利用Erianin调节关键的炎症信号.

科学领域:

神经科学是一个神经科学.
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

长期使用吗啡和由质瘤引起的压力会使疼痛管理和瘤进展复杂化.
在这些过程中涉及的Janus激酶2/信号转换器和转录3 (JAK2/STAT3) 途径的激活器.

研究的目的:

调查Erianin在缓解吗啡耐受性和抑制质瘤进展方面的有效性.
阐明Erianin作用背后的分子机制,重点关注JAK2/STAT3通路.

主要方法:

使用质瘤携带的,对吗啡耐受性小鼠模型.
评估了Erianin对止痛,瘤生长和分子信号传递的影响.
进行了多omics分析 (转录组学,miRNA-seq) 来识别调节性microRNAs.

主要成果:

埃里亚宁可将吗啡耐受性降低50%和质瘤进展率降低60%.
埃里亚宁抑制了JAK2 / STAT3信号传递,并抑制了背脊根结质 (DRG) 中的大脑衍生神经营养因子 (BDNF).
确定了miR-375和miR-20a作为针对JAK2的关键调节剂,影响神经炎症和吗啡耐受性.

结论:

埃里亚宁在治疗疼痛和抑制质瘤进展方面表现出治疗潜力.
JAK2/STAT3通路和特定的微RNA是干预的关键目标.
这些发现为疼痛管理中的精密瘤治疗提供了分子基础.

关键词:

质瘤是一种质瘤.JAK2/STAT3 3 的情况.在癌症中微RNA调节.吗啡耐受性吗啡耐受性在瘤学瘤学.

相关概念视频

01:22

PI3K/mTOR/AKT Signaling Pathway

5.4K

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

5.4K

02:38

Mitogens and the Cell Cycle

7.7K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

7.7K

02:07

Tumor Progression

7.2K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

7.2K

01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

672

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

672

03:03

mTOR Signaling and Cancer Progression

4.6K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

4.6K

01:15

Drugs that Stabilize Microtubules

2.6K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

2.6K